E-602 is under clinical development by Palleon Pharmaceuticals and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how E-602’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
E-602 is under development for the treatment of solid tumors including melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, gastric cancer, gastroesophageal junction carcinoma, transitional cell cancer (urothelial cell cancer), head and neck cancer and pancreatic cancer. The drug candidate is a first in class bi-specific fusion protein developed based on an enzyme-antibody glyco-ligand editing (EAGLE) platform. It is administered through intravenous route.
Palleon Pharmaceuticals overview
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company is headquartered in Waltham, Massachusetts, the US
For a complete picture of E-602’s drug-specific PTSR and LoA scores, buy the report here.